Roche (ROG.CH), is turning a new page in the company’s history after acquiring rights to an obesity therapy from Denmark’s Zealand Pharma (ZEAL.DK).
The deal signals a renewed push by Roche to catch up with obesity market leaders Novo Nordisk (NOVOB.DK) and Eli Lilly (LLY.US).
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appUnder the agreement, Zealand Pharma will receive $1.65 billion upfront with the possibility of milestone payments, bringing the total to $5.3 billion, depending largely on late-stage trials and sales development, Roche said.
Zealand Pharma shares rose 26% following the announcement.
Jefferies analysts wrote in a note that they believe that Zealand Pharma's petrelintide could be better than Novo Nordisk's CagriSema, hence the nearly 4% discount in the company's shares.
Source: Distribution of rates of return in the pharmaceutical sector. Source: xStation
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
